Loading
A phase 3 trial of Durvalumab in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting.
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients is a phase 3 interventional study registered as NCT03706690 by AstraZeneca, with 407 participants enrolled, started 2018-11-27 and due to reach its primary completion in 2024-06-23. Interventions recorded: Durvalumab. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
407 enrolled.
95% CI 10.9 to 18.0; Figures from the ClinicalTrials.gov results section (first posted 2025-02-12), not from a publication · 95% CI 5.4 to 13.8
Source95% CI 29.0 to 42.9; Figures from the ClinicalTrials.gov results section (first posted 2025-02-12), not from a publication · 95% CI 20.6 to 40.4
SourceFigures from the ClinicalTrials.gov results section (first posted 2025-02-12), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-Free Survival (PFS) (Modified Intent-to-Treat [mITT] Set)primary | Durvalumab | 252 | 14 months | 0.75 (0.578 to 0.986) | 0.038 | link |
| Placebo | 129 | 6.5 months | ||||
| Overall Survival (OS), ITT set | Durvalumab | 272 | 38.4 months | 0.87 (0.656 to 1.166) | 0.346 | link |
| Placebo | 135 | 32.5 months | ||||
| Objective Response Rate (ORR), ITT set | Durvalumab | 240 | 27.1% | - | 0.128 | link |
| Placebo | 127 | 19.7% |
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Unresectable stage III non-small-cell lung cancer, Durvalumab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.